OncoArendi has an option agreement exclusive to the MSU for small molecule inhibitors

OncoArendi Therapeutics has entered into exclusive license option agreements with University of Michigan-based Innovation Partnerships to develop new small molecule inhibitors of undisclosed protein to treat fibrotic diseases, the company said.
The new inhibitors were initially developed and validated as a result of a long-term research collaboration with the Michigan State University (MSU). The University of Michigan entered into an option license agreement with OncoArendi on both its own and MSU's behalf, it said.

“The cooperation with the University of Michigan, one of the leading research institutions in the world, is an opportunity for us to develop further thanks to the combination of the University of Michigan's competence in identifying new biological targets in potential therapy of fibrotic diseases with OncoArendi's experience in the development of small molecule drugs in this therapeutic area. At OncoArendi, we continue to develop an innovative portfolio of small molecules that modulate the functions of new protein targets involved in inflammatory, fibrotic and neoplastic processes, ”said Nicolas Beuzen, Business Development Director of OncoArendi Therapeutics, quoted in the release.

OncoArendi Therapeutics is an innovative biotechnology company specializing in the search, development and commercialization of new drugs for the treatment of respiratory diseases and cancer. The company has been listed on the GPW main market since April 2018. In 2020, it had PLN 125 million of consolidated revenues.


Our privacy policy
%d bloggers like this: